Why Becton, Dickinson and Company (BDX) stock moved
Updated Sep 29, 2026
Becton, Dickinson and Company (BDX) shares fell 1.0% to $181.97 as of September 29, 2026, a modest decline from the prior close of $183.83. BestStocks flagged the session as a major change for BDX. The move is tied to price move up. Below, we break down what changed for BDX, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
What happened
BDX fell 1.0% to $181.97
BDX fell 1.0% in its latest session, moving from $183.83 to $181.97.
Material / EarningsWeak confidence
Rel. volume
0.7×
Below Avg
Vs peers
—
No comparable peers
Market cap
$50.1B
New York Stock Exchange
Analyst target
$187
+2.7% vs price
Price chart
Aug 31 – Sep 29
E earnings
F filing
A analyst
V/N other
click a marker to highlight
Change events — click to jump to details
What it means for Becton, Dickinson and Company investors
For Becton, Dickinson and Company investors, the recent signals add up to a bearish shift. On the constructive side: Positive price momentum; Positive price momentum. Weighing against that: Material negative event; Negative session, down 1.0%. Wall Street's consensus price target sits at $186.88, implying +2.7% upside from $181.97. BestStocks rates the overall signal quality weak (36/100). With earnings roughly 37 days out, the next report is the most likely near-term test of the move.
BDX price reaction
BDX last traded at $181.97, down $1.86 (-1.01%) from the previous close of $183.83. The session traded on 0.7× average volume (below avg), so participation was unremarkable. Over the past month the stock has ranged between $176.42 and $188.11, and it currently sits about 47% of the way up that band.
Bullish and bearish analyst opinions on Becton, Dickinson and Company (BDX)
The consensus analyst price target on Becton, Dickinson and Company (BDX) is $186.88, 2.7% above the recent $181.97. Over the past 90 days analysts logged 0 upgrades, 8 maintains, and 0 downgrades. Here is how the bullish and bearish cases on BDX line up.
▲ The bullish case
+Wall Street's consensus price target of $186.88 implies +2.7% upside from $181.97.
+The Street's most bullish target is $210.00 (+15.4%).
+Positive price momentum.
+Becton, Dickinson and Company (BDX) moved +3.26% from $154.88 to $159.93 on 2026-07-16, reaching a new 30-day high.
▼ The bearish case
−The most bearish analyst target is $159.00 (-12.6%).
−Material negative event.
−Negative session, down 1.0%.
−BDX moved -3.67% from $156.30 to $150.56 on 2026-07-08.
Bull vs bear balanceBearish Shift
BearishNeutralBullish
Weighing both sides, BestStocks' composite read of recent signals is bearish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Sep 29, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Becton, Dickinson and Company (BDX) moved +0.66% from $179.76 to $180.94 on 2026-09-18. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. The move was accompanied by volume 3.5x the 5-day average, suggesting institutional participation without an identified trigger.
BDX fell 2.04% to $176.13 on September 10, 2026, amid institutional portfolio adjustments—including stake trimming by large firms like HighTower Advisors—and residual digestion following management's presentation at the Wells Fargo Healthcare Conference on September 9, per web research. The decline occurred on below-average volume (0.61x expected at 240 minutes into session), with the stock underperforming sector peers.
BDX fell 2.81% to $179.54 amid macroeconomic headwinds and a leadership transition, with Gary Sorsher officially becoming chief quality officer on September 8 (per web sources). The decline also coincides with an upcoming dividend ex-date of September 9, 2026 ($1.05 per share), which can trigger pre-ex-date profit-taking. Volume at 370,975 shares 80 minutes into the session ran 1.11x the historical average—normal for this time of day.
Material / Earnings2026-08-21+2.3%
Becton, Dickinson and Company (BDX) moved +2.12% from $188.02 to $192.00 on 2026-08-21, reaching a new 30-day high on modestly elevated volume (1.6x the 5-day average). We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found.
Material / Earnings2026-08-20+0.0%
Becton, Dickinson and Company (BDX) moved +0.76% from $186.20 to $187.62 on 2026-08-20. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. The move coincided with BDX reaching a new 30-day high on volume near its 5-day average.
Material / Earnings2026-08-19+3.8%
Becton, Dickinson and Company (BDX) moved +2.12% from $183.71 to $187.60 on 2026-08-19, reaching a new 30-day high. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found.
Material / Earnings2026-08-12+1.2%
Becton, Dickinson and Company (BDX) moved +3.09% from $178.07 to $183.58 on 2026-08-12, reaching a new 30-day high. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found.
Becton, Dickinson and Company moved +4.96% intraday from $170.66 to $179.13. Becton Dickinson (BDX ) stock is up over 3.7% on August 6, 2026, after reporting fiscal Q3 earnings that beat Wall Street estimates on both the top and bottom lines, alongside an upgraded full-year profit outlook. Q3 Financial Beats - Adjusted EPS: Reported at $3.23 , topping the consensus estimate of $3.14. - Revenue: Reached $4.98 billion , coming in ahead of expectations of $4.89 billion and marking a 5.4% increase year-over-year. Guidance and Business Momentum - Raised Outlook: Management tightened and raised the lower end of its full-year 2026 adjusted EPS guidance to a range of $12.62 to $12.72. - Strong Segments: Growth was bolstered by strong execution and robust demand in core areas, including its biologic drug delivery segment (such as the Vystra injection pen tied to GLP-1 demand). If you want, I can also share: - Analyst price targets following this report - A breakdown of segment-by-segment revenue performance - Details on the recent business spin-off affecting comparisons Let me know what else you'd like to check!
Upcoming catalysts & outlook
Next earnings
2026-11-05 (est.)
in 37 days
Thesis shift
Bearish Shift
bearish signal
Risk level
Medium
from change events
Frequently asked questions about BDX
Why did Becton, Dickinson and Company (BDX) stock move?
BDX fell 1.0% to $181.97. No single company-specific catalyst was confirmed during the move window, and it looks technical.
How much did BDX stock fall?
BDX lost 1.01% ($1.86) versus the prior close of $183.83, last trading at $181.97 on 0.7× average volume.
When is Becton, Dickinson and Company's next earnings date?
BDX's next earnings report is estimated for 2026-11-05 — about 37 days away.
What is the analyst price target for BDX?
The consensus analyst price target for BDX is $186.88, about 2.7% above the current $181.97. Over the past 90 days, analysts recorded 0 upgrades, 8 maintains, and 0 downgrades.
How BestStocks tracks BDX
This page is generated automatically by BestStocks' change-detection system after price move up was detected and verified against independent data sources. It draws on 20 tracked change events for BDX, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of September 29, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.
